Two Sigma Advisers
LVTX

Two Sigma Advisers’s LAVA Therapeutics LVTX Stock Holding History

Two Sigma Advisers’s Portfolio LVTX Stock Details LVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-26,900
Closed -$44.7K – 2446
2024
Q3 		$44.7K Sell
26,900
-4,800
-15% -$8.79K ﹤0.01% 2220
2024
Q2 		$57.1K Buy
31,700
+15,000
+90% +$39.6K ﹤0.01% 2354
2024
Q1 		$55.6K Buy
+16,700
New +$36.7K ﹤0.01% 2345

Other funds holding LVTX

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $369M AUM 50.95% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
PFA
Pathway Financial Advisors South Burlington, Vermont $857M AUM 17.21% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
EGM
Engineers Gate Manager New York $7.71B AUM 24.88% 1-Year Est. Return

Two Sigma Advisers's LVTX Position: Q4 2024 in Review

Two Sigma Advisers sold out of LAVA Therapeutics (LVTX) in Q4 2024, closing a stake of 26,900 shares — an estimated $44.7K sold.

Two Sigma Advisers first reported a position in LVTX in Q1 2024 and held it in 3 quarters. The position peaked at $57.1K in Q2 2024. 22 funds tracked by Wall St. Rank hold LVTX as of Q4 2024.

  • Two Sigma Advisers reported no remaining LAVA Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Two Sigma Advisers sold 26,900 LAVA Therapeutics shares in Q4 2024, an estimated $44.7K.
  • Two Sigma Advisers first reported a position in LAVA Therapeutics in Q1 2024 and held it in 3 quarters.
  • Two Sigma Advisers's LAVA Therapeutics position peaked at $57.1K in Q2 2024.
  • 22 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q4 2024.

Based on Two Sigma Advisers's 13F filing for Q4 2024, filed 14 Feb 2025.